A study in The New England Journal of Medicine evaluates the combination of nirmatrelvir and ritonavir against COVID-19, finding it does not significantly reduce symptom duration in vaccinated or unvaccinated adult outpatients.
New Health Impact Investment Platform launches to strengthen primary care
Execution is starting under the new Health Impact Investment Platform on the first country health investment plans turning original commitment into operational reality.